CereScan and Molecular Imaging of Colorado Add TRICARE to Approved Insurers
"Serving the needs of our nation's military population has been a long-term objective of CereScan," said
Traumatic brain injuries and PTSD are two of the most common diagnoses soldiers receive after returning from battle. Although an estimated 10-20% of veterans experience some form of traumatic brain injury, only a small fraction receive proper diagnosis and treatment.
For many veterans who are experiencing one or both of these debilitating disorders, following the best course of treatment is difficult without an accurate diagnosis. That's where CereScan makes all the difference. CereScan's SPECT imaging technology goes beyond traditional diagnostic tools to review cerebral blood flow and cellular processes that help accurately diagnose traumatic brain injuries, helping physicians and patients create an effective treatment plan.
"Our research through the 'Invisible Brain Injury Project', as well as other outreach efforts related to understanding and treating their wounds of war, particularly as it relates to chronic Traumatic Brain Injury, is indicative of our commitment to them," Kelley added "The addition of TRICARE to our list of insurers provides greater opportunity to assist those most in need."
Molecular Imaging of
CereScan is the nation's leader in providing statistically measured brain diagnostics based on a new generation of imaging software, PET/CT (Positron Emission Tomography/Computed Tomography) and SPECT (Single Photon Emission Computed Tomography) neuroimaging technologies. Referring and treating medical experts can rely on CereScan to offer differentiated diagnoses on a wide array of brain-based disorders including:
• Traumatic Brain Injury
• Toxic Brain Injury
• Alzheimer's Disease
• Mild Cognitive Impairment
• Other Dementias
• Parkinson's Disease
• Obsessive Compulsive Disorder
• Bipolar Disorder
• ADD/ADHD
• Anxiety Disorder
About CereScan
CereScan combines state-of-the-art SPECT and PET/CT brain imaging technologies with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the neurological basis of their conditions. In a variety of legal settings, CereScan provides objective evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit http://www.CereScan.com.
Read the full story at http://www.prweb.com/releases/2015/12/prweb13140708.htm



First shots fired in Virginia General Assembly's health care battle
Advisor News
- Gov. Kim Reynolds signs health insurance premium tax increase into law
- Gov. Reynolds signs temporary tax hike to address Iowa Medicaid shortfall
- Temporary tax hike to fill Medicaid gap heads to governor
- Iowa Senate sends health insurer tax increase to governor’s desk
- Temporary tax hike to fill Iowa Medicaid gap heads to governor’s desk
More Advisor NewsAnnuity News
- Corebridge, Equitable merge to create potential new annuity sales king
- LIMRA: Final retail annuity sales total $464.1 billion in 2025
- How annuities can enhance retirement income for post-pension clients
- We can help find a loved one’s life insurance policy
- 2025: A record-breaking year for annuity sales via banks and BDs
More Annuity NewsHealth/Employee Benefits News
- New study finds mental health care is Horry County's biggest unmet need
- After ACA subsidies expired, millions of Americans don't have health care
- New Managed Care Study Results Reported from Yale University School of Medicine (Association of Social Determinants of Health with Utilization of SGLT2 Inhibitors and GLP1 Receptor Agonists: A Systematic Review and Meta-Analysis): Managed Care
- How Federal Funding Cuts Will Cost 500,000 New Yorkers Their Health Insurance
- Small business owners are state's backbone but obstacles to growth remain: DiNapoli
More Health/Employee Benefits NewsLife Insurance News
- Corebridge, Equitable Merger Creates $1.5tr Platfrom
- AM Best Removes from Under Review with Positive Implications and Affirms Credit Ratings of Sompo Seguros Mexico S.A. de C.V.
- Corebridge, Equitable merge to create potential new annuity sales king
- Aflac adds new long-term care rider
- AM Best Affirms Credit Ratings of Nan Shan General Insurance Co., Ltd.
More Life Insurance News